Shopping Cart
Remove All
Your shopping cart is currently empty
Felzartamab(MOR-202) is a human-targeted monoclonal antibody to CD38 for the study of multiple myeloma and advanced antibody-mediated rejection of allogeneic kidney transplants.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | In Stock | In Stock | |
| 5 mg | $647 | In Stock | In Stock | |
| 10 mg | $987 | - | In Stock |
| Description | Felzartamab(MOR-202) is a human-targeted monoclonal antibody to CD38 for the study of multiple myeloma and advanced antibody-mediated rejection of allogeneic kidney transplants. |
| In vitro | MOR202-mediated toxic effects on multiple myeloma (MM) cell lines can be enhanced by the proteasome inhibitor bortezomib (BOR) and the immunomodulator lenalidomide (LEN).[1] |
| In vivo | MOR202 (12 mg/kg; murine MM models) dose-dependently reduced osteolysis by up to 55%. Coadministration with 0.6 mg/kg BOR or 50 mg/kg LEN completely eliminated osteolysis at a low dose of 3 mg/kg.[1] |
| Synonyms | TJ-202, MOR-202, MOR-03087 |
| Molecular Weight | 143.65 kDa |
| Cas No. | 2197112-39-1 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.